Stocks-PTGX-Protagonist Therapeutics Inc

PTGX Protagonist Therapeutics Inc

14.28 0.23 (1.63%)
Delayed Prices By NASDAQ, in USD Market Open
Invest
Invest

Overview

Prev Close14.06
Day's Range 14.00 - 14.74
52 Week Range 6.84 - 29.52
Average Volume (3M)886.89K
1-Year Return-51.58%
Beta1.4742
Market Cap691.73M
P/E Ratio
Revenue35.2M
EPS-2.6684
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.719/08/202201/11/202213/01/20238.009.0010.0011.0012.0013.0014.0015.00
Chart times in UTC
Industry Biotechnology
CEO Dinesh V. Patel, PhD
Employees 118

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Protagonist Therapeutics Inc's revenues decreased by 4.44% and amounted to 27.36M. Net income decreased by 89.80% to -125.55M. Net assets increased by 7.30% to 300.02M and EPS decreased from -1.92 to -2.71.
PTGX's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
90.49%
Net Profit Margin
-8,557.54%
Operating Margin
-377.22%
Return On Investment
-44.97%
12/21
03/22
06/22
09/22
Total Revenue
8.62M
25.72M
859K
0
Gross Profit
N/A
N/A
N/A
-853K
Operating Income
-37.92M
-21.11M
-41.44M
-32.3M
Net Income
-36.91M
-20.93M
-41.04M
-31.23M